R R

What Is Nubeqa?

Nubeqa is a prescription medication containing darolutamide, an androgen receptor inhibitor used to treat certain forms of prostate cancer. It is approved for adults with non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. In metastatic castration-sensitive disease, Nubeqa can be used with androgen deprivation therapy, with or without docetaxel according to the prescribed regimen. It is an oral targeted hormonal treatment, not traditional cytotoxic chemotherapy.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Nubeqa?

Nubeqa is a prescription medication containing darolutamide, an androgen receptor inhibitor used to treat certain forms of prostate cancer. It is approved for adults with non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. In metastatic castration-sensitive disease, Nubeqa can be used with androgen deprivation therapy, with or without docetaxel according to the prescribed regimen. It is an oral targeted hormonal treatment, not traditional cytotoxic chemotherapy.

read more about nubeqa ...

Copy this HTML:

Copy HTML Copied!

How Does Nubeqa Work?

Nubeqa blocks androgen receptors, preventing testosterone and other androgens from activating signals that promote prostate cancer cell growth. Some prostate cancers continue to depend on androgen signaling even when testosterone levels have been reduced through hormone therapy. Darolutamide interferes with this pathway and helps limit cancer progression. Nubeqa does not replace the need for medical or surgical castration when indicated and is generally used as part of a broader prostate cancer treatment plan.

What Types of Prostate Cancer Does Nubeqa Treat?

Nubeqa is approved for non-metastatic castration-resistant prostate cancer, in which the disease progresses despite castrate testosterone levels without detectable distant metastases. It is also approved for metastatic castration-sensitive prostate cancer, which has spread beyond the prostate but remains responsive to testosterone suppression. Nubeqa may be used with docetaxel in selected metastatic cases. Treatment selection depends on disease stage, previous therapies, medical history, and the oncology team's assessment.

How Should Nubeqa Be Taken?

The recommended Nubeqa dose is 600 mg orally twice daily with food, using the prescribed tablet strength. Tablets should be swallowed whole. Patients should continue treatment with a gonadotropin-releasing hormone medication unless they have undergone bilateral orchiectomy. Dose reductions may be necessary for moderate liver impairment, severe kidney impairment, adverse reactions, or certain medication interactions. When docetaxel is included, its schedule is coordinated separately by the oncology team. Do not change the prescribed dose without medical guidance.

What Are the Side Effects and Warnings of Nubeqa?

Possible side effects include fatigue, musculoskeletal pain, rash, and changes in laboratory findings. Nubeqa carries warnings for ischemic heart disease, seizures, and liver injury, including drug-induced liver injury. Additional side effects can occur when it is combined with docetaxel. Darolutamide can also harm an unborn baby, requiring contraception precautions for patients with partners who can become pregnant. New chest pain, seizures, jaundice, or significant weakness require medical evaluation.

Common Questions About Nubeqa

Is Nubeqa a hormone therapy?

Yes. Nubeqa is an androgen receptor inhibitor used as targeted hormonal therapy for certain forms of prostate cancer.

Can Nubeqa treat metastatic prostate cancer?

Yes. Nubeqa is approved for metastatic castration-sensitive prostate cancer and can be prescribed with or without docetaxel according to the treatment regimen.

How often is Nubeqa taken?

Nubeqa is generally taken twice daily with food. The standard total daily dose is 1,200 mg, although certain patients require dose adjustments.

Does Nubeqa replace androgen deprivation therapy?

No. Patients generally continue medical testosterone suppression during Nubeqa treatment unless they have undergone bilateral orchiectomy.

References

DailyMed - NUBEQA (darolutamide) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a7cb212-56e4-4b9d-a73d-bfee7fe4735e. Date Accessed October 19, 2026.

Darolutamide. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK590050/. Date Accessed October 19, 2026.

Darolutamide. MedlinePlus. https://medlineplus.gov/druginfo/meds/a619045.html. Date Accessed October 19, 2026.

Darolutamide. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/darolutamide. Date Accessed October 19, 2026.

Darolutamide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Darolutamide. Date Accessed October 19, 2026.